|
Dr. Clark, associate professor in the department of neurology at the University of Cincinnati, is collaborating with Avicena to advance the company's clinical programs in Creatine Transporter Defect (CTD). He is a highly regarded expert in the chemistry, biochemistry and physiology of creatine and creatine kinase. Dr Clark is credited with being the first person to purify creatine kinase from vascular smooth muscle and he has conducted some of the first experiments on creatine's effects on arteries.
In collaboration with the Avicena Group, Dr. Clark is a co-lead investigator of a pilot study to assess the ability of creatine supplementation to restore normal levels of creatine in the central nervous system and improve cognition amongst patients with CTD. Further, Dr. Clark is developing a preclinical model for CTD which will allow for rapid screening of different therapies.
An author of approximately 60 publications in peer-reviewed journals, Dr. Clark has also authored or co-authored two texts (Creatine and Creatine Phosphate; Academic Press, 1996) and holds ten patent applications or patents. An active participant in national committees, Dr. Clark was the president of the Guanidino Compounds in Biology and Medicine Society (1997 - 2001).
Dr. Clark received a B.A. in chemistry with a biology minor from Susquehanna University, Selinsgrove, PA. He then attended Michigan State University where he obtained an M.S. in biophysics and a Ph.D. in physiology. Following a post-doctorate at the University of Paris in the department of biophysics, Dr. Clark was a lecturer in the department of biochemistry at Oxford University where he continued to study the role and importance of creatine and creatine kinase in cardiovascular and cerebral vascular diseases. | 